| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine Hydrochloride manufacturers
|
| | 2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine Hydrochloride Basic information |
| | 2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine Hydrochloride Chemical Properties |
| | 2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine Hydrochloride Usage And Synthesis |
| Uses | 2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine Hydrochloride is the HCl salt of 2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine which is a selective 5-HT6 receptor agonist. It has been proven to have antidepressant and anxiolytic effects on rats suggesting its usefulness as a potential antidepressant. | | in vivo | Acute administration of WAY-181187 (3-30 mg/kg, s.c.) hydrochloride significantly increases extracellular GABA concentrations without altering the levels of glutamate or norepinephrine in the rat frontal cortex. Additionally, WAY-181187 (30 mg/kg, s.c.) hydrochloride produces modest yet significant decreases in cortical dopamine and 5-HT levels[1]. | Animal Model: | Adult male Sprague-Dawley rats weighing 280-350 g[1] | | Dosage: | 3, 10, or 30 mg/kg | | Administration: | Acute dministered by s.c. | | Result: | Significantly increased extracellular GABA concentrations without altering the levels of glutamate or norepinephrine.
|
| | IC 50 | 5-HT6 Receptor: 2.2 nM (Ki); 5-HT6 Receptor: 6.6 nM (EC50) |
| | 2-[1-[(6-Chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]-1H-indol-3-yl]ethylamine Hydrochloride Preparation Products And Raw materials |
|